Thus, the synergistic association between combinatory PD-1/PD-L1 inhibitors and VA therapy in patients with advanced or metastasised NSCLC as observed in the present study joins the ranks of previous achievements. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.